James River Group Holdings (JRVR) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Net income from continuing operations was $14.5M for Q2 2024, up 19.4% year-over-year, with adjusted net operating income of $12.7M, reflecting strong investment income and improved profitability.
The sale of JRG Re closed in April 2024, resulting in discontinued operations and a $1.4M loss on disposal year-to-date.
A $160M adverse development cover and loss portfolio transfer (LPT-ADC) for E&S was executed, effective January 1, 2024, with a $44M pre-tax income reduction expected in Q3.
Gross written premiums declined 2.6% in Q2, with net written premiums down 11.3%, mainly due to lower retention and program changes.
The board continues to explore strategic alternatives for the company, with no set timeline for completion.
Financial highlights
Combined ratio for Q2 2024 was 99.3%, compared to 98.9% a year ago; expense ratio improved to 26.3%.
Loss ratio increased to 73.0% from 70.7% year-over-year, mainly due to $10.7M adverse reserve development in E&S lines.
Net investment income rose 36.7% to $24.9M, with an embedded book yield of 4.6%–5.0%.
Net realized and unrealized investment losses totaled $2.3M, mainly from equity and bank loan portfolios.
Shareholders’ equity per share was $14.32 at June 30, 2024, up 0.8% sequentially.
Outlook and guidance
The LPT-ADC reinsurance contract will result in a ~$44M pre-tax income reduction in Q3 2024, with recoveries recognized in Q3.
Sale of JRG Re expected to increase future cash flows and support U.S. operations growth.
Board declared a $0.05/share dividend payable September 30, 2024.
Continued focus on profitable growth in SME-weighted E&S and Specialty Admitted segments.
Latest events from James River Group Holdings
- 2025 marked a sharp turnaround to profitability, capital growth, and E&S-driven operational gains.JRVR
Q4 202527 Mar 2026 - Q3 2024 net loss of $40.7M driven by reserve charges, reinsurance, and strategic capital actions.JRVR
Q3 202415 Jan 2026 - Over 21 million common shares registered for resale by major investors, with no proceeds to the company.JRVR
Registration Filing16 Dec 2025 - Q4 2024 net loss of $92.7M; E&S premiums top $1B; 2025 outlook positive.JRVR
Q4 202416 Dec 2025 - Annual Meeting to vote on directors, auditor, compensation, and incentive plan amendments.JRVR
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor re-appointment, compensation, and plan amendments.JRVR
Proxy Filing2 Dec 2025 - Q1 net income dropped to $9M as E&S pricing rose and Specialty Admitted premiums declined.JRVR
Q1 202524 Nov 2025 - Q2 2025 saw $11.7M adjusted net income, 14% return, and record E&S premiums amid strategic changes.JRVR
Q2 202523 Nov 2025 - Strong underwriting and cost discipline drove a 19.3% return and 94% combined ratio.JRVR
Q3 202514 Nov 2025